"Game-Changing" CAR T-Cell Therapy Offers Hope for Multiple Sclerosis Patients

Strategic Insights -

Multiple sclerosis patient Emily Henders, 37, has become the first person in the UK to receive CAR T-cell therapy to treat the condition. Henders, a biology teacher, was diagnosed with multiple sclerosis on Christmas Eve in 2021 and has since experienced four debilitating relapses. Despite taking one of the most effective medications for the disease, Henders has seen her symptoms worsen, causing her to worry about the impact on her children.

She received the CAR T-cell treatment at University College London Hospital (UCLH) last week, which is part of a global clinical trial to see if it can treat MS. The therapy works by genetically engineering the patient's own T cells to recognize and kill B cells, which cause damage and allow MS to advance. Henders reported feeling "really good" after the infusion, with no nausea, fevers, or energy loss.

"The CAR T-cell treatment has the potential to transform lives by halting or slowing the progression of the disease," said Dr. Claire Roddie, a consultant haematologist at UCLH. "Our ultimate goal is to achieve long periods of disease remission with a single, one-time CAR T-cell treatment, enabling patients to come off all their other medications." The therapy has already shown success in cancer and autoimmune diseases like lupus.

Key Takeaways:

  • Emily Henders, a 37-year-old biology teacher, is the first patient in the UK to receive CAR T-cell therapy for multiple sclerosis.
  • Henders was diagnosed with MS on Christmas Eve in 2021 and has experienced four debilitating relapses despite taking highly effective medication.
  • The CAR T-cell therapy, part of a global clinical trial, works by genetically engineering the patient's own T cells to recognize and kill B cells that cause damage and allow MS to advance.
  • Henders reported feeling no side effects and "really good" after the three-minute infusion.
  • The therapy has the potential to transform lives by halting or slowing the progression of the disease, with an ultimate goal of achieving long periods of disease remission with a single treatment.
  • Dr. Claire Roddie, a consultant haematologist at University College London Hospital, believes the therapy could enable patients to come off all their other medications.

Statistics:

  • Up to 18 patients will be recruited globally by early 2027 for the trial.
  • The CAR T-cell treatment modifies the T cells to recognize and kill B cells, which are known to cause damage and allow MS to advance.
  • Patients with MS often experience a high probability of needing a wheelchair, a risk that the therapy aims to prevent.

Sources:

  • Emily Henders, personal interview, "I'm feeling normal and I've got energy back."
  • Dr. Claire Roddie, consultant haematologist at University College London Hospital, "Our ultimate goal is to achieve long periods of disease remission with a single, one-time CAR T-cell treatment."
  • Caitlin Astbury, senior research communications manager at the MS Society, "It's early days but, if trial results prove successful, CAR T-cell therapy could be a game-changer for how we treat the condition."
  • University College London Hospital (UCLH), Press Release, "New CAR T-cell treatment for MS shows promise in early trial results."